SpyGlass Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
44.6%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$2.31next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| BIM-IOL System Four-Year Efficacy and Safety Follow-Up Data | 31 Dec 2026 |
| BIM-DRS First-in-Human Trial Initiation | 31 Dec 2026 |
| Phase 3 Trials (SGP-005 and SGP-006) Full Enrollment Completion | 31 Dec 2027 |
Monitoring Framework
Key Performance Indicators
BIM-IOL System Phase 3 Patient Enrollment QuarterlyTarget: 800 patients (approx. 400 per trial across SGP-005 and SGP-006)
Cash Runway and Liquidity Quarterly251MTarget: Fund planned operations through 2028
BIM-IOL System Phase 1/2 Long-Term Follow-Up (Off-Drop Rate) Annually98.0%Target: Maintain high percentage of patients drop-free at 12-month and subsequent readouts
Watch Items
- Phase 3 Clinical Trial Enrollment Progress (SGP-005 and SGP-006)Trigger: Slower-than-expected enrollment extending past 2027 targetAction: Evaluate site expansion, increase investigator engagement, or adjust clinical trial protocols.
- BIM-DRS (Bimatoprost Drug Ring System) First-in-Human Trial InitiationTrigger: Delay in starting the trial beyond the second half of 2026Action: Review preclinical animal data, regulatory submissions, and clinical site readiness.
- R&D Cash Burn RateTrigger: Quarterly R&D expenses exceeding $15 million without proportional clinical milestonesAction: Re-evaluate clinical trial operational efficiencies and optimize site management costs.
Research as of 24 Jul 2026